Key statistics dashboard for BioAtla, Inc. (BCAB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Stock Data
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.07 |
| Price / Book | -0.08 |
| P/S | 0.34 |
| P/FCF | -0.12 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -4.15% |
| EBIT Margin | -345.53% |
| EBITDA Margin | -343.24% |
| Operating Margin | -372.06% |
| Net Margin | -370.05% |
Financial Health
| Current Ratio | 0.20 |
| Quick Ratio | 0.20 |
| Cash Ratio | 0.07 |
| Debt / Equity | -0.16 |
| Debt / Assets | 61.68% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -70.06 |
Per-Share Data
| Revenue per share | 5.12 |
| Book Value per share | -21.82 |
| Cash per share | 0.93 |
| FCF per share | -14.14 |
| Tangible Book Value per share | -21.82 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.67 |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks